ML141 (CID-2950007) is demonstrated to be a potent, selective and reversible non-competitive inhibitor of Cdc42 GTPase suitable for in vitro assays, with IC50 of 200 nM and selectivity against other members of the Rho family of GTPases (Rac1, Rab2, Rab7). ML141 is associated with an increase in p38 activation and may induce p38-dependent apoptosis/senescence. ML141 […]
More Information Supplier PageML141 (CID-2950007) is demonstrated to be a potent, selective and reversible non-competitive inhibitor of Cdc42 GTPase suitable for in vitro assays, with IC50 of 200 nM and selectivity against other members of the Rho family of GTPases (Rac1, Rab2, Rab7). ML141 is associated with an increase in p38 activation and may induce p38-dependent apoptosis/senescence. ML141 […]
More Information Supplier PageLY2584702 is a selective, ATP-competitive p70S6K inhibitor with IC50 of 4 nM.
More Information Supplier PageLY2584702 is a selective, ATP-competitive p70S6K inhibitor with IC50 of 4 nM.
More Information Supplier PageObeticholic Acid (INT-747) is a potent and selective farnesoid X receptor (FXR) agonist with EC50 of 99 nM. Obeticholic Acid inhibits autophagy. Phase 3.
More Information Supplier PageKartogenin (KGN) is an activator of the smad4/smad5 pathway, and promotes the selective differentiation of multipotent mesenchymal stem cells into chondrocytes.
More Information Supplier PageKartogenin (KGN) is an activator of the smad4/smad5 pathway, and promotes the selective differentiation of multipotent mesenchymal stem cells into chondrocytes.
More Information Supplier PageDefactinib (VS-6063, PF-04554878) is a selective, and orally active FAK inhibitor. Phase 2.
More Information Supplier PageDefactinib (VS-6063, PF-04554878) is a selective, and orally active FAK inhibitor. Phase 2.
More Information Supplier PageDefactinib (VS-6063, PF-04554878) is a selective, and orally active FAK inhibitor. Phase 2.
More Information Supplier Page
